Fit.Hm
FIT.HM is a pharmaceutical company that generates revenue primarily through the development and commercialization of prescription drugs and therapies.
Business. FIT.HM is a pharmaceutical company operating within the Healthcare sector, specifically engaged in pharmaceuticals and medical research. The firm generates revenue through a product-sale model, with key performance indicators including pipeline depth, research and development expenditure, and cash runway. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segmental breakdowns.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
FIT.HM is a pharmaceutical company operating within the Healthcare sector, specifically engaged in pharmaceuticals and medical research. The firm generates revenue through a product-sale model, with key performance indicators including pipeline depth, research and development expenditure, and cash runway. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segmental breakdowns.
FIT.HM maintains a capital structure with a debt-to-equity ratio of 0.43, indicating a relatively balanced mix of debt and equity financing. The company's liquidity position is characterized as medium, with a current ratio of 2.82, suggesting it can cover its short-term obligations but with limited excess capacity. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints.
In terms of profitability, FIT.HM reports a return on equity (ROE) of 1.03% and a return on assets (ROA) of 0.5%, both of which are below the typical thresholds for strong performance in the pharmaceutical industry. The company's operating margin is 5.3%, and its net profit margin is 1.93%, which are both in line with the industry's median performance.
FIT.HM's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the provided data. This lack of diversification may expose the company to higher operational and market risks, particularly in the event of a downturn in its primary therapeutic area or geographic market.
The company's growth trajectory is modest, with no specific revenue growth rates provided in the data. However, the free cash flow is negative at -50.46 million, and capital expenditures are substantial at -264.29 million, indicating a heavy investment in infrastructure or R&D. These expenditures may be necessary to sustain long-term growth but could also pressure short-term profitability.
The risk assessment for FIT.HM highlights a medium liquidity risk and a low dilution risk. The company's negative net cash position after debt is a key flag, suggesting potential challenges in maintaining liquidity without external financing. The dilution risk is low, with no significant dilution potential identified in the basic shares outstanding.
Recent events, as reflected in the financial data, include a significant capital expenditure and a negative free cash flow, which may indicate ongoing investment in the business or a temporary cash flow constraint. No specific filings or transcripts are cited in the provided data to support further details on recent events.
- FIT.HM has a balanced capital structure with a debt-to-equity ratio of 0.43.
- The company's ROE and ROA are below typical thresholds for strong performance in the pharmaceutical industry.
- Revenue is concentrated in a single business segment, with no geographic diversification disclosed.
- Free cash flow is negative, and capital expenditures are substantial, indicating ongoing investment.
- The company faces medium liquidity risk and low dilution risk.
- Recent financial data shows significant capital expenditures and a negative free cash flow.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- FIT.HM Market data — financials · 2026-05-27